Literature DB >> 6432031

Studies on experimental chronic active hepatitis in the rabbit. II. Immunological findings.

R C Butler.   

Abstract

The role played by humoral and cellular immune response to liver antigens in the pathogenesis of experimental chronic active hepatitis (CAH) was studied in rabbits which had been immunized with the two human liver-specific proteins LSP and LP2, with LSP alone, or with an extract of human skeletal muscle. Rabbits immunized with LSP, alone or with LP2, developed skin test reactivity and circulating antibody to homologous LSP; liver biopsy revealed immunoglobulin bound to the hepatocyte cell surface. It has been suggested that cellular immunity to homologous LSP or alternatively, antibody to an antigenic determinant shared by human and rabbit LSP, may play a role in the pathogenesis of experimental CAH, but both abnormalities were present in two rabbits which did not develop CAH despite observation for at least 18 months. Five normal rabbits given an intravenous injection of serum pooled from rabbits with CAH did not develop significant hepatic lesions. Immunity to homologous LSP or other hepatocyte cell surface antigens could not be detected in any rabbit which had been immunized with skeletal muscle, and hepatocytes from these rabbits did not have immunoglobulin on their cell surface. The pathogenesis of CAH in these animals is obscure. These findings suggest that mechanisms other than an auto-immune response to LSP play an important role in the pathogenesis of experimental chronic active hepatitis.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6432031      PMCID: PMC2040985     

Source DB:  PubMed          Journal:  Br J Exp Pathol        ISSN: 0007-1021


  12 in total

1.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

2.  The role of myofibrillar fraction of skeletal muscle in the production of experimental polymyositis.

Authors:  D Manghani; T A Partridge; J C Sloper
Journal:  J Neurol Sci       Date:  1974-12       Impact factor: 3.181

3.  Experimental chronic active hepatitis in rabbits following immunization with human liver proteins.

Authors:  K H Büschenfelde; F K Kössling; P A Miescher
Journal:  Clin Exp Immunol       Date:  1972-05       Impact factor: 4.330

4.  Studies on the pathogenesis of experimental chronic active hepatitis in rabbits. I. Induction of the disease and protective effect of allogeneic liver specific proteins.

Authors:  K H Meyer zum Büschenfelde; U Hopf
Journal:  Br J Exp Pathol       Date:  1974-10

5.  Studies on the pathogenesis of experimental chronic active hepatitis in rabbits. II. Demonstration of immunoglobulin on isolated hepatocytes.

Authors:  U Hopf; K H Meyer zum Büschenfelde
Journal:  Br J Exp Pathol       Date:  1974-10

6.  Purification and characterization of human liver-specific membrane lipoprotein (LSP).

Authors:  I G McFarlane; B M Wojcicka; G M Zucker; A L Eddleston; R Williams
Journal:  Clin Exp Immunol       Date:  1977-03       Impact factor: 4.330

7.  The liver specific protein: evidence for species-specific and non-species-specific determinants.

Authors:  M Manns; K H Meyer zum Büschenfelde; T Hütteroth; U Hopf
Journal:  J Clin Lab Immunol       Date:  1980-01

8.  Immunological reactions to liver-specific membrane lipoprotein (LSP) in experimental autoimmune liver disease in rabbits.

Authors:  R M Uibo; H J Helin; K J Krohn
Journal:  Clin Exp Immunol       Date:  1982-05       Impact factor: 4.330

9.  Lymphocyte cytotoxicity to autologous hepatocytes in HBsAg-negative chronic active hepatitis.

Authors:  G M Vergani; D Vergani; P J Jenkins; B Portmann; A P Mowat; A L Eddleston; R Williams
Journal:  Clin Exp Immunol       Date:  1979-10       Impact factor: 4.330

10.  Histological and immunological investigation of liver-specific protein (LSP) immunized rabbits compared with patients with liver disease.

Authors:  C Feighery; G S McDonald; J F Greally; D G Weir
Journal:  Clin Exp Immunol       Date:  1981-07       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.